London/Brussels — The EU is in talks with Gilead Sciences Inc. about reserving a “sufficient number of doses” of remdesivir for the bloc’s member states after the US forged a deal to snap up almost all the drugmaker’s supplies.

Discussions are ongoing, a European Commission spokesperson told reporters Thursday. Remdesivir is one of only two medicines with a proven effect against the coronavirus, and the EU expects to clear it as a Covid-19 treatment by the end of this week...

Subscribe now to unlock this article.

Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).

There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.

Cancel anytime.

Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.

Speech Bubbles

Please read our Comment Policy before commenting.